

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. TJU-1156	Serial No. 08/203,004
		Applicant David Berd	
		Filing Date February 28, 1994	Group Unknown
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JKS	AA	Anichini A. et al. Cytotoxic T Lymphocyte Clones From Peripheral Blood and From Tumor Site Detect Intratumor Heterogeneity of Melanoma Cells <i>J. Immunol</i> 1989 142:3692	
JKS	AB	Berd et al., Augmentation of the Human Immune Response by Cyclophosphamide <i>Cancer Res.</i> 1982 42:4862-4866	
JKS	AC	Berd et al., Impairment of Concanavalin A-inducible Suppressor Activity following Administration of Cyclophosphamide to Patients with Advanced Cancer <i>Cancer Res.</i> 1984 44:1275-1280	
JKS	AD	Berd et al., Induction of Cell-mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with A Melanoma Cell Vaccine Preceded by Cyclophosphamide <i>Cancer Res.</i> 1986 46:2572-2577	
JKS	AE	Berd et al., Active Immunotherapy of Human Melanoma Exploiting the Immunopotentiating Effects of Cyclophosphamide <i>Cancer Invest.</i> 1988 6:337-349	
JKS	AF	Berd et al., Potentiation of Human cell-mediated and Humoral Immunity by Low-Dose Cyclophosphamide <i>Cancer Res.</i> 1984 44:5439-5443	
JKS	AG	Berd et al., Effect of Low Dose Cyclophosphamide on the Immune System of Cancer Patients: Reduction of T-Suppressor Function without Depletion of the CD8+ Subset ¹ <i>Cancer Res.</i> 1987 47:3317-3321	
JKS	AH	Berd et al., Effect of Low Dose Cyclophosphamide on the Immune Systems of Cancer Patients: Depletion of CD4+, 2H4+ Suppressor-inducer T-Cells ¹ <i>Cancer Res.</i> 1988 48:1671-1675	
JKS	AI	Berd et al., An Unusual Pattern of Tumor Regression in Melanoma Patients Treated with Cyclophosphamide (CY) + Autologous Tumor Cell Vaccine <i>Proc Amer. Assoc. Cancer Res.</i> 1988 29:408	
JKS	AJ	Berd et al., Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases <i>Cancer Res.</i> 1991 51:2731	
EXAMINER Julie K Staples		DATE CONSIDERED 3-28-95	

Form PTO-1449 Modified		Docket No. TJU-1156	Serial No. 08/203,004
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David Berd	
		Filing Date February 28, 1994	Group Unknown
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JKS	AK	Berendt M.J. T-Cell-Mediated Suppression of Anti-Tumor Immunity <i>J. Exp. Med.</i> 1980 151:69	
JKS	AL	Boerrigter and Scheper Local and Systemic Desensitization Induced by Repeated Epicutaneous Hapten Application <i>J. Invest. Dermatol.</i> 1987 88:3	
JKS	AM	Butler J.E. The Amplified ELISA: Principles of and Applications for the Comparative Quantitation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Separates <i>Methods Enzymol.</i> 1981 73:482	
JKS	AN	Bystryn J. Antibody Response and Tumor Growth in Syngeneic Mice Immunized to Partially Purified B16 Melanoma-Associated Antigens <i>J. Immun.</i> 1978 120:96	
JKS	AO	Fearon E.R. et al Interleukin-2 Production by Tumor cells Bypasses T Helper Function in the Generation of an Antitumor Response Cell 1990 60:397	
JKS	AP	Flood et al., Protective Immunity To Progressive Tumors Can Be Induced by Antigen Presented on Regressor Tumors <i>J. Immunol</i> 1987 138:3573-3579	
JKS	AQ	Fujiwara H. et al., The Augmentation of <i>In Vitro</i> and <i>In Vivo</i> Tumor-Specific T cell-Mediated Immunity by Amplifier T Lymphocytes <i>J. Immunol</i> 1980 124:863	
JKS	AR	Fujiwara et al., Enhanced TNP-Reactive Helper T Cell Activity and its Utilization in the Induction of Amplified Tumor Immunity that Results in Tumor Regression <i>J. Immunol</i> 1984 132:1571-1577	
JKS	AS	Fujiwara et al., Establishment of A Tumor-Specific Immunotherapy Model Utilizing TNP-Reactive Helper T Cell Activity and Its Application of The Autochthonous Tumor System <i>J. Immunol.</i> 1984 133:510-514	
JKS	AT	Geczy A.F. et al. Lymphocyte Transformation in Contact Sensitivity <i>Immunol.</i> 1970 19:189	
EXAMINER		DATE CONSIDERED	
Julie K Staples		3-24-95	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. TJU-1156	Serial No. 08/203,004
		Applicant David Berd	
		Filing Date February 28, 1994	Group Unknown
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JKS	AU	Lotze et al., Systemic Administration of Interleukin-2 in Humans <i>J. Biol. Response</i> 1982 3:475-482	
JKS	AV	Meuer et al., Low-Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg In Immunodeficient Non-Responders to Hepatitis B Vaccination <i>Lancet</i> 1989 1:15-18	
JKS	AW	Miller and Claman, The Induction of Hapten-Specific T Cell Tolerance by Using Hapten-Modified Lymphoid Cells <i>J. Immunol</i> 1976 117:1519-1526	
JKS	AX	Mitchison, Immunologic Approach to Cancer Transplant <i>Proc.</i> 1970 2:92-103	
JKS	AY	Mukherji B. et al. Regulation of Cellular Immune Response Against Autologous Human Melanoma <i>J. Immunol</i> 1986 136:1888	
JKS	AZ	Old L.J. Cancer Immunology: The Search for Specificity - G.H.A. Clowes Memorial Lecture <i>Cancer Res.</i> 1981 41:361	
JKS	BA	Ortmann, B. et al, Synthetic Peptides Anchor T Cell-Specific TMP Eptiopes to MHC Antigens <i>J. Immunol.</i> 1992 148:1445	
JKS	BB	Rotzschke et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells <i>Nature</i> 1990 348:252	
JKS	BC	Ruiter MHC antigens in human melanomas D.J. <i>Seminars in Cancer Bio</i> 1991 2:35	
EXAMINER		DATE CONSIDERED	
Julie K. Staples		3-24-95	

Form PTO-1449 Modified		Docket No. TJU-1156	Serial No. 08/203,004
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David Berd	
		Filing Date February 28, 1994	Group Unknown
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JKS	BD	Shearer F.M. Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic lymphocytes <i>J. Immunol</i> 1974 4:527	
JKS	BE	Talmadge et al., Systematic Preclinical Study on the Therapeutic Properties of Recombinant Human Interleukin 2 for the Treatment of Metastatic Disease <i>Cancer Res.</i> 1987 47:5725-5732	
JKS	BF	Topalian et al., Immunotherapy of Patients with Advanced cancer Using Tumor-Infiltrating Lymphocytes and Recombinant Interleukin-2: A Pilot Study <i>J. Clin. Oncol.</i> 1988 6:839-853	
JKS	BG	Townsend S.E. Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells <i>Science</i> 1993 259:368	
JKS	BH	Tsutsui H. et al. Drug-Specific T Cells Derived From patients with drug-Induced Allergic Hepatitis <i>J. Immunol</i> 1992 149:706	
JKS	BI	Van derBruggen P. et al. The Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma <i>Science</i> 1991 254:1643	
JKS	BJ	West et al., Constant-Infusion Recombinant interleukin-2 in Adoptive Immunotherapy of Advanced Cancer <i>New Eng. J. Med.</i> 1987 316:898-903	
JKS	BK	Wysocki and Sato "Panning" for lymphocytes: A method for cell selection <i>Proc. Natl. Acad. Sci. USA</i> 1978 75:2844	
JKS	BL	Yamamura et al. Defining Protective Responses to pathogens: Cytokine Profiles in Leprosy Lesions <i>Science</i> 1991 254:277	
EXAMINER Julie K. Staples		DATE CONSIDERED 3-24-95	

